Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SOLV
SOLV logo

SOLV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
76.264
Open
75.720
VWAP
75.14
Vol
12.83M
Mkt Cap
12.98B
Low
74.200
Amount
964.21M
EV/EBITDA(TTM)
10.78
Total Shares
173.17M
EV
17.88B
EV/OCF(TTM)
118.39
P/S(TTM)
1.61
Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.
Show More

Events Timeline

(ET)
2026-04-30
12:10:00
Solventum Shares Up 2.6% After Trian Sends Letter to Board
select

News

PRnewswire
1.0
05-27PRnewswire
Solventum to Speak at Jefferies Healthcare Conference
  • Conference Participation: Solventum's management will participate in a fireside chat at the Jefferies Healthcare Conference on June 3, 2026, starting at approximately 9:55 a.m. EDT, showcasing the company's latest advancements in the healthcare sector.
  • Live and Archived Replay: The fireside chat will be available for live streaming and archived replay on the company's website, ensuring that investors and stakeholders can access relevant information at any time, thereby enhancing transparency and communication efficiency.
  • Mission Statement: Solventum is committed to driving transformation in the healthcare industry through innovative solutions at the intersection of health, materials, and data science, aiming to improve patient lives and empower healthcare professionals to perform at their best, thereby demonstrating its leadership in the sector.
  • Brand Image Development: As a new company, Solventum emphasizes its breakthrough solutions in addressing customer challenges, aiming to enhance its brand image and attract more investor attention through continuous innovation.
CNBC
6.0
05-15CNBC
Wall Street's Latest Upgrade Calls Overview
  • RXO Upgrade: Stifel upgraded RXO from hold to buy, citing a favorable market setup emerging into the latter half of 2026, particularly at the intersection of improving brokerage fundamentals and unique idiosyncratic levers, indicating potential growth opportunities.
  • Cisco Rating Boost: HSBC upgraded Cisco to buy from hold following the company's recent earnings report, raising the price target from $77 to $137, reflecting strong momentum in AI infrastructure and improved earnings visibility.
  • Arista Networks Upgrade: Raymond James upgraded Arista Networks from market perform to outperform, anticipating improved sales growth in 2027 and beyond, particularly as the company expands into AI backend and campus applications, enhancing its market share.
  • Dell Reiteration: Morgan Stanley reiterated its overweight rating on Dell, raising the price target from $205 to $280, expecting the company to raise its FY27 earnings guidance again, although supply visibility still needs to catch up with the high demand outlook for AI servers.
seekingalpha
9.5
05-06seekingalpha
Solventum Corporation Q1 2026 Earnings Call Insights
  • Performance Exceeds Expectations: Solventum reported Q1 sales of $2 billion, reflecting a 2.1% organic growth year-over-year, while reported sales decreased by 3%, with earnings per share at $1.48, indicating resilience and growth potential in the market.
  • Capital Return Strategy: CEO Bryan Hanson announced board approval for up to $1 billion in share buybacks, with expectations to accelerate execution, aimed at enhancing shareholder value and boosting market confidence.
  • Product Innovation and Transformation: The company plans to launch nearly 20 new products over the next two years and is implementing a $500 million 'Transform for the Future' program to drive long-term growth and competitive positioning in the market.
  • Operational Efficiency Gains: CFO Wayde McMillan highlighted that over 50% of transition service agreements have been exited, with a target of over 90% by the end of 2026, which will further optimize operational efficiency and cost structure.
Globenewswire
6.5
04-30Globenewswire
Solventum's Spin-Out Boosts Executive Pay, Not Shareholder Value
  • Executive Pay Surge: Since its spin-out from 3M, Solventum's CEO has received over $80 million in compensation within two years, while the company's market capitalization stands at only $12 billion, indicating a significant imbalance between executive pay and shareholder value.
  • Shareholder Value Erosion: Following the spin-off, Solventum has erased $13 billion in shareholder value compared to the projected $25 billion market cap, reflecting management's failure to effectively enhance company performance, leading to shareholder disappointment.
  • Shareholder Concerns Ignored: Despite Trian Fund Management owning nearly 5% of shares and actively engaging with the Board, Solventum has yet to take action to enhance shareholder value, demonstrating management's disregard for shareholder needs.
  • Unimplemented Improvement Proposals: Trian's three proposed initiatives, including right-sizing overhead, simplifying the business portfolio, and improving capital allocation, could significantly enhance company value if implemented, but no substantial progress has been observed so far.
Newsfilter
6.5
04-30Newsfilter
Solventum's Spin-Out Mismanagement Raises Concerns
  • Shareholder Value Loss: Following its spin-out from 3M, Solventum has seen a staggering $13 billion loss in shareholder value compared to the projected $25 billion market cap, indicating significant management failures that directly impact investor returns.
  • Executive Compensation Controversy: The CEO of Solventum has received over $80 million in compensation over the past two years, while the company's market cap stands at only $12 billion, raising serious concerns among shareholders about governance and compensation practices.
  • Shareholder Concerns Ignored: Despite Trian Fund Management owning nearly 5% of Solventum and attempting to engage with the Board, the company has yet to take action to enhance shareholder value, reflecting a troubling disregard for shareholder input that could lead to further shareholder attrition.
  • Proposed Improvement Initiatives: Trian has outlined three actionable initiatives, including right-sizing overhead, simplifying the business portfolio, and prioritizing share repurchases, aimed at restoring performance and rebuilding shareholder trust, which, if implemented, could significantly enhance the company's value.
seekingalpha
8.5
04-30seekingalpha
Trian Investor Pushes for Changes at Solventum
  • Investor Pressure: Activist investor Trian has sent a new letter to Solventum's board urging the company to separate its dental products and software operations, pushing for necessary structural changes to address current performance challenges.
  • Stock Fluctuation: Following Trian's pressure, Solventum's shares rose by 1.7%, yet the stock has dropped 17% this year, reflecting market concerns about the company's future and its response to investor suggestions.
  • Capital Allocation Issues: Trian has expressed dissatisfaction with Solventum's capital allocation plans, arguing that the company needs to reassess its resource distribution to restore performance levels akin to those during its time within 3M, highlighting the urgency in strategic execution.
  • Performance Recovery Goals: In January 2025, Trian sent a letter to Solventum's board requesting the company to develop a plan to restore performance, aiming for 2%-3% organic sales growth while optimizing its product portfolio and expanding margins.
Wall Street analysts forecast SOLV stock price to rise
8 Analyst Rating
Wall Street analysts forecast SOLV stock price to rise
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
79.00
Averages
93.71
High
105.00
Current: 0.000
sliders
Low
79.00
Averages
93.71
High
105.00
Wedbush
Michael Piccolo
Outperform
initiated
$94
AI Analysis
2026-05-15
Reason
Wedbush
Michael Piccolo
Price Target
$94
AI Analysis
2026-05-15
initiated
Outperform
Reason
Wedbush analyst Michael Piccolo initiated coverage of Solventum with an Outperform rating and $94 price target.
Wedbush
Outperform
initiated
$94
2026-05-15
Reason
Wedbush
Price Target
$94
2026-05-15
initiated
Outperform
Reason
As previously reported, Wedbush initiated coverage of Solventum (SOLV) with an Outperform rating and $94 price target as the firm believes shares represent a compelling, multi-catalyst special situation offering asymmetric upside potential. Spun off from 3M (MMM) on April 24, Solventum has underperformed expectations during its early standalone tenure, with adjusted EBIT compressing about 480 basis points from pre-spin levels. However, Wedbush thinks the stock's current 9.6 times EV/EBITDA multiple materially undervalues a portfolio of market-leading franchises across MedSurg, Dental Solutions, and Health Info Systems, each of which commands premium positions in their respective peer groups.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SOLV
Unlock Now

Valuation Metrics

The current forward P/E ratio for Solventum Corp (SOLV.N) is 11.59, compared to its 5-year average forward P/E of 12.32. For a more detailed relative valuation and DCF analysis to assess Solventum Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
12.32
Current PE
11.59
Overvalued PE
13.60
Undervalued PE
11.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.45
Current EV/EBITDA
18.25
Overvalued EV/EBITDA
11.84
Undervalued EV/EBITDA
7.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.47
Current PS
1.55
Overvalued PS
1.63
Undervalued PS
1.31

Financials

AI Analysis
Annual
Quarterly

Whales Holding SOLV

M
Madison Avenue Partners, LP
Holding
SOLV
+24.04%
3M Return
D
Discovery Capital Management, LLC
Holding
SOLV
+11.10%
3M Return
P
Parsons Capital Management, Inc.
Holding
SOLV
+7.62%
3M Return
G
General American Investors Company, Inc.
Holding
SOLV
+6.31%
3M Return
3
3M Company
Holding
SOLV
+2.67%
3M Return
H
HBK Investments L.P.
Holding
SOLV
+2.46%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Solventum Corp (SOLV) stock price today?

The current price of SOLV is 74.95 USD — it has decreased -1.3

What is Solventum Corp (SOLV)'s business?

Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.

What is the price predicton of SOLV Stock?

Wall Street analysts forecast SOLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOLV is93.71 USD with a low forecast of 79.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Solventum Corp (SOLV)'s revenue for the last quarter?

Solventum Corp revenue for the last quarter amounts to 2.01B USD, decreased -3.04

What is Solventum Corp (SOLV)'s earnings per share (EPS) for the last quarter?

Solventum Corp. EPS for the last quarter amounts to 0.07 USD, decreased -91.03

How many employees does Solventum Corp (SOLV). have?

Solventum Corp (SOLV) has 20000 emplpoyees as of May 31 2026.

What is Solventum Corp (SOLV) market cap?

Today SOLV has the market capitalization of 12.98B USD.